EBITDA: Income before interest, taxes, depreciation and amortization.
Enanta Pharmaceuticals, Inc. (ENTA) had EBITDA of $-17.67M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$18.31M |
|
$-18.25M |
|
-- |
|
$18.31M |
|
$37.21M |
|
$-18.89M |
|
$0.67M |
|
$-18.23M |
|
$-18.23M |
|
$-18.25M |
|
$-18.25M |
|
$-18.25M |
|
$-18.25M |
|
$-18.89M |
|
|
EBITDA |
$-17.67M |
21.38M |
|
21.38M |
|
$-0.85 |
|
$-0.85 |
|
| Balance Sheet Financials | |
$222.71M |
|
$36.62M |
|
$78.32M |
|
$301.03M |
|
$44.55M |
|
-- |
|
$177.20M |
|
$221.75M |
|
$79.28M |
|
$79.28M |
|
$79.28M |
|
21.38M |
|
| Cash Flow Statement Financials | |
$-12.78M |
|
$38.05M |
|
$-18.30M |
|
$41.20M |
|
$48.17M |
|
$6.97M |
|
$14.53M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-103.16% |
|
-103.16% |
|
-- |
|
-99.52% |
|
-99.68% |
|
$-24.22M |
|
-- |
|
-- |
|
-- |
|
0.06 |
|
-- |
|
2.19 |
|
41.07 |
|
-23.03% |
|
-23.03% |
|
-6.06% |
|
-23.03% |
|
$3.71 |
|
$-1.13 |
|
$-0.60 |
|